Merck Units To Pay $44M In Rebif Whistleblower Suit

Law360, New York (May 4, 2011, 5:53 PM EDT) -- Merck KGaA affiliates have agreed to pay $44.3 million to resolve a whistleblower’s allegations that they bought off health care providers to promote or prescribe the multiple sclerosis drug Rebif, resulting in tainted Medicare and Medicaid claims, federal authorities announced Wednesday.

The agreement with pharmaceutical manufacturers Serono Laboratories Inc., EMD Serono Inc., Merck Serono SA, and Ares Trading SA also settles a False Claims Act suit that whistleblower Tim Amato lodged against the companies in Maryland federal court in 2005.

Amato, who worked as a regional...
To view the full article, register now.